Life Sciences venture capital firm Forbion Capital Partners has closed its its Forbion Capital Fund II Co-invest Fund I (FCF II Co-Invest) at €75M.
This new fund vehicle has been set up to allow Forbion’s existing LPs to back later-stage, de-risked companies within the existing FCF II portfolio with additional growth capital.
The new Co-Invest Fund will invest in up to six existing FCF II portfolio companies, alongside FCF II, in what are likely to be the final financing rounds by these companies before exit.
Led by Managing Partners Sander Slootweg and Martien van Osch, Forbion Capital Partners invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. The firm has invested in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda (ACOR), Fovea, Insmed (INSM), PanGenetics, Argenta Discovery, BioVex, Pathway Medical, CircuLite, bluebird bio (BLUE), uniQure (QURE), Argos (ARGS), arGEN-X (ARGX.BR), Santaris, PneumRx, AM Pharma and Promedior.
Including the new fund FCF III, Forbion manages €635M across six funds. The firm, which has offices in Naarden, The Netherlands, Munich, Germany and representation in Boston, US, also operates a joint venture with BioGeneration Ventures, who manage two separate seed and early stage funds focused on Benelux.